The installation industry, particularly in the residential segment, has seen a remarkable surge in stock performance over the past month. Companies operating in this sector, such as Masco Corp. (MAS), Installed Building Products Inc. (FIX), and nVent Electric plc. (NVT), have all contributed to this impressive performance.
šTickers in Industry - $NBIX, $ACAD, $ALKS, $MDXG, $CYCCP, $VCEL, $VTGN, $MRNAĀ
Choppy Market Trader, Popular Stocks: Market Neutral Strategy (TA&FA)Ā -Ā Annualized Return + 107%
Theme and Group of Tickers Inside the Theme
The theme in focus here is the installation industry, with a specific emphasis on companies engaged in manufacturing home products and items related to home improvement. The notable tickers within this theme include:
Market Cap
The average market capitalization for companies within the installation theme is approximately $5.6 billion. However, there is significant variation within this group, with market caps ranging from $52.3 million to $13.4 billion. Masco Corp. (MAS) holds the highest valuation at $13.4 billion, while the lowest valued company is KEQU at $52.3 million.
High and Low Price Notable News
In the past month, stocks within the installation theme have experienced substantial price movements. On average, these stocks have seen a remarkable monthly price growth of 19.6%. The average weekly price growth was 6.44%, and the average quarterly price growth was 25.83%.
Notable price movements in this theme include Masco Corp. (MAS) witnessing a significant weekly decline of -5.16% and, in contrast, a weekly gain of +5.43%. nVent Electric (NVT) also saw a notable weekly gain of +5.79%, reflecting the volatility and potential for substantial returns in this sector.
Volume
The trading volumes for stocks in the installation theme have exhibited some interesting trends. On average, there was a weekly volume decrease of -4.76% in the past month, while the monthly and quarterly volume trends showed even more significant declines of -34.01% and -16.5%, respectively.
It's worth noting that nVent Electric's stock witnessed a remarkable daily volume growth of 99% of the 65-Day Volume Moving Average on August 1, 2023. Similarly, Griffon stock experienced a one-day volume surge, reaching a growth of 296% of the 65-Day Volume Moving Average on June 17, 2023.
Fundamental Analysis Ratings
While specific fundamental analysis ratings are not provided in the information given, it's clear that the installation industry, particularly in the residential segment, is exhibiting strong performance. The impressive monthly price growth of 19.6% underscores the sector's potential for investors seeking growth opportunities.
The installation industry, encompassing companies involved in home improvement and related products, has shown outstanding stock performance over the past month. Investors should take note of the opportunities presented by stocks like Masco Corp. (MAS), Installed Building Products Inc. (FIX), and nVent Electric plc. (NVT) in this thriving sector.
NBIXĀ :Ā On November 24, 2023, NBIX exhibited a noteworthy shift in its trajectory as it crossed above its 50-day Moving Average. Historically, such occurrences have often translated into positive momentum, with 32 out of 39 comparable instances resulting in subsequent price increases over the following month. With an 82% probability, the odds appear favorable for NBIX to sustain its upward trajectory. Investors may find this development an encouraging sign for potential gains in the near future.
ACADĀ :Ā ACAD Pharmaceuticals recently exhibited a notable shift in its stock trajectory, breaching its 50-day Moving Average on December 5, 2023. This movement signifies a potential reversal from its previous upward momentum to a bearish trend. Historical analysis reveals that in 35 out of 45 comparable scenarios, ACAD's stock experienced further decline in the subsequent month. This pattern suggests a 78% probability of the stock continuing its downward trend. Investors and market analysts are closely monitoring this development, considering its implications for future investment strategies and market positioning related to ACAD.
ALKSĀ :Ā ALKS Pharmaceuticals exhibited a significant shift in market sentiment as its Momentum Indicator ascended above the zero mark on November 16, 2023. This transition is widely interpreted as a precursor to a new upward trend in the stock's performance. Investors and traders are advised to consider strategies like purchasing shares or opting for call options in anticipation of potential gains. Tickeron's A.I.dvisor analyzed 95 comparable events where the indicator turned positive. In 76 of these instances, ALKS's stock price increased in the subsequent period, indicating an 80% likelihood of a continued upward movement. This trend presents a promising opportunity for market participants focusing on ALKS.
Ā
The RSI Indicator for NBIX moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 20 of the 28 cases the stock moved higher. This puts the odds of a move higher at 71%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on NBIX as a result. In 62 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for NBIX just turned positive on October 20, 2026. Looking at past instances where NBIX's MACD turned positive, the stock continued to rise in 35 of 53 cases over the following month. The odds of a continued upward trend are 66%.
Following a +2.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in 222 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
NBIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for NBIX moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
The Aroon Indicator for NBIX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. NBIXās price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 56 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.005) is normal, around the industry mean (8.801). P/E Ratio (20.643) is within average values for comparable stocks, (-2.500). Projected Growth (PEG Ratio) (0.280) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (4.587) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a product based biopharmaceutical company
Industry PharmaceuticalsGeneric